The effects of diltiazem and its derivative, TA3090 on the Ba-induced inward current were investigated using dispersed smooth muscle cells of the rabbit mesenteric artery. Diltiazem and TA3090 inhibited the inward current, in a concentration-dependent manner, and TA3090 was more potent than diltiazem (IC50 for diltiazem was 300 mumol/l and for TA3090, 30 mumol/l). The inward current completely recovered from the inhibitory actions of diltiazem (100 mumol/l) after its removal at holding potentials of -60 and -40 mV, though complete recovery did not occur after TA3090 (1-100 mumol/l). The voltage-dependent inactivation curves were shifted to the left by both drugs. Judging from the amplitudes of shift of V-half, the dissociation constants of inhibition for both diltiazem and TA3090 in the inactivated state were 17 mumol/l and 2.6 mumol/l, respectively. At a holding potential of -60 mV, diltiazem and TA3090 reduced the peak amplitude of the inward current, and diltiazem, but not TA3090, accelerated the decay of the current (300 ms command pulse duration). However, TA3090 did accelerate the decay of the current when a longer pulse (1 s) was applied, or when a depolarizing pulse was applied from a holding potential of -80 mV. Changes in the pH (range 6.8-7.7) of the bathing solution did not influence the decay of the current. In conclusion, TA3090 inhibits the Ca-channels of smooth muscle cells of the rabbit mesenteric artery, in a voltage-dependent manner, and its inhibitory actions are similar to those of diltiazem. However, TA3090 has much longer and stronger inhibitory actions on the Ba-inward current than diltiazem.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00180664DOI Listing

Publication Analysis

Top Keywords

diltiazem ta3090
20
inhibitory actions
16
actions diltiazem
12
ta3090
12
smooth muscle
12
muscle cells
12
cells rabbit
12
rabbit mesenteric
12
mesenteric artery
12
decay current
12

Similar Publications

Ameliorating effect of clentiazem (TA-3090), a new Ca antagonist, on the impaired learning ability of poststroke SHRSP.

Pharmacol Biochem Behav

April 1995

Pharmacological Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, Japan.

We investigated the influence of clentiazem (8-chloro-diltiazem, (+)(2S,3S)-3-acetoxy-8-chloro-5-[2-(dimethyl-amino)ethyl]-2,3-dihydro-2- (4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one maleate, TA-3090) and other Ca antagonists on the impaired learning ability in poststroke spontaneous hypertensive rats stroke prone (SHRSP) using a shuttle box. SHRSP were given 1% NaCl solution as drinking water until the development of stroke (poststroke SHRSP). Active avoidance task was started from the fourth day after the onset of stroke.

View Article and Find Full Text PDF

Antihypertensive drug classes such as thiazide diuretics, angiotensin-converting enzyme inhibitors, beta-adrenergic blocking agents, peripheral alpha 1-antagonists, and central alpha 2-agonists all describe therapeutic agents that are quite similar to each other and strikingly different from members of the other classes. A glaring exception is the rubric "calcium channel blocker," under which strikingly dissimilar drugs have been lumped. Although the phenylalkylamines (verapamil and gallapamil) and benzothiazepines (diltiazem and TA3090) bind at different receptors on the alpha 1 component of the calcium channel, they are reasonably similar in their clinical pharmacology.

View Article and Find Full Text PDF

Clentiazem (a novel calcium antagonist) and its basic metabolites (MB1-MB7) showed inhibitory effects on collagen-induced platelet aggregation in human platelets. All the basic metabolites (IC50:8-22 micrograms/ml) had much stronger inhibitory effects than clentiazem itself (IC50:53 micrograms/ml), but the acidic metabolites (MA1-MA4) had no inhibitory effects even at 300 micrograms/ml. Other calcium antagonists (diltiazem, verapamil, nicardipine and nimodipine) also showed similar inhibitory effects although nicardipine and nimodipine were less active than the other drugs.

View Article and Find Full Text PDF

We previously reported the renal hemodynamic effects of different antihypertensive regimens in uninephrectomized, alloxan-induced, diabetic (DM) beagle dogs following one year of treatment. Dogs were prospectively randomized to one of five groups (N = 26): nondiabetic controls, Group I; dogs with DM on no antihypertensive drugs, Group II; dogs on a converting enzyme inhibitor, lisinopril (L), Group III; dogs on a calcium antagonist, TA3090 (diltiazem-like), Group IV; and dogs on a combination of each drug, in reduced doses, Group V. The current paper extends our previous studies by describing the morphologic changes that occurred within each group of dogs studied.

View Article and Find Full Text PDF

Antihypertensive therapy and progression of diabetic renal disease.

J Cardiovasc Pharmacol

September 1994

Department of Preventive Medicine, Rush Presbyterian/St. Luke's Medical Center, Chicago, Illinois.

A number of changes in intrarenal hemodynamics and morphology are characteristic of diabetic nephropathy. These changes include: increases in intraglomerular pressure and volume, glomerular capillary permeability to macromolecules, and mesangial matrix expansion. Most antihypertensive drugs attenuate some of the increases in these parameters.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!